|Nombre||Título||Pagar||Ejecutado||Año de nacimiento|
|Mr. Stephen R. Davis J.D.||CEO & Director||1.03M||N/D||1961|
|Mr. Mark C. Schneyer||Exec. VP & CFO||555.49k||N/D||1974|
|Mr. Brendan P. Teehan||Exec. VP, COO & Head of Commercial||486.47k||N/D||1969|
|Mr. Austin D. Kim||Exec. VP, Gen. Counsel & Sec.||559.24k||N/D||1964|
|Mr. James K. Kihara||VP, Chief Accounting Officer & Corp. Controller||N/D||N/D||1981|
|Mr. Bob Mischler||Sr. VP of Strategy & Technology Operations||N/D||N/D||N/D|
|Mr. Mark C. Johnson||VP of Investor Relations||N/D||N/D||N/D|
|Ms. Julie Fisher||Sr. VP of Marketing & Commercial Strategy||N/D||N/D||N/D|
|Mr. Rob Ackles||Sr. VP & Chief People Officer||N/D||N/D||N/D|
|Ms. Ponni Subbiah M.D., M.P.H.||SVP, Global Head of Medical Affairs & Chief Medical Officer||N/D||N/D||N/D|
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
La calificación ISS Governance QuickScore de ACADIA Pharmaceuticals Inc. a partir del 28 de enero de 2023 es 6. Las puntuaciones principales son Auditoría: 7; Junta: 6; Derechos del accionista: 8; Compensación: 5.